FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC

On October 11, 2023, the U.S. FDA granted approval to Encorafenib and Binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the Encorafenib and Binimetinib regimens, as well as the underlying biology for these therapies, with three internationally known clinicians and researchers.